On June 11, 2026, a delegation from the Health Business Development Department of Yuexiu Group visited the Shenzhen-Hong Kong Cell Valley for site inspection and exchange. The two sides held comprehensive, in-depth discussions on topics including the current state of the cell and gene therapy (CGT) market in Guangdong Province, regional industry demand, policy directions, technology translation challenges, and commercial implementation pathways.

The visiting delegation was led by Feng Weicheng, General Manager of the Health Business Development Department of Yuexiu Group, together with Liu Yingjie and Li Yutian, both Directors, as well as Deng Zhongfan, Strategic Account Manager at Danaher (Shanghai) Management Co., Ltd. Representing the Cell Valley Group were Chairman and General Manager Shi Yuanyuan, Chief Scientist Wang Jianxun, and Deputy General Manager Xiang Hua, who hosted the delegation throughout and, drawing on the company's development practices and industry insights, shared a comprehensive overview of the CGT industry landscape, platform development achievements, and regional cooperation experience.

During the exchange, the Yuexiu Health team toured the Shenzhen-Hong Kong Cell Valley's smart exhibition hall, observing the Cell Valley Group's full-process operations in cell drug development, quality control testing, and scaled manufacturing. They gained direct insight into the Group's endtoend development model spanning basic research, clinical development, and commercial implementation, and learned in detail about its standardized CGT service system, compliance operations, and achievements in industrial ecosystem development.

At the symposium, Shi Yuanyuan, drawing on industry policies and practical case studies, offered an in-depth interpretation of the new "technology + drug" dual-track regulatory landscape in China's domestic CGT industry. He systematically analyzed the market pain points and development opportunities for CGT clinical research and industrial implementation in Guangdong, and introduced the Cell Valley Group's practical achievements in collaborating with over a hundred toptier tertiary hospitals across China and advancing multiple IIT projects. He noted that the Guangdong-Hong Kong-Macao Greater Bay Area has a pronounced CGT industry clustering effect and a well-developed industrial chain. The Cell Valley Group is eager to leverage its platform, technological, and resource advantages, particularly in the construction of the Guangzhou Cell Valley project, and hopes to carry out multilevel cooperation with Yuexiu Health to jointly tap into the development potential of Guangdong's CGT industry.

Feng Weicheng remarked that Yuexiu Health is actively moving into the biomedical sector. As industry regulations continue to standardize, the CGT industry has entered a phase of highquality development. Guangdong, with its robust industrial supporting capabilities and abundant clinical resources, has become a core region for corporate transformation and strategic deployment. This visit aimed to precisely assess the regional market situation and development trends, while also looking forward to a strong partnership with the Cell Valley Group. By leveraging the Group's mature operational experience and fullchain service capabilities, Yuexiu Health hopes to jointly explore investment cooperation and project implementation, and work together to strengthen and expand the regional CGT industry.

This exchange built a bridge for communication and collaboration between the two sides. Going forward, both parties will actively explore diverse models of investment cooperation, project implementation, and resource sharing, jointly promoting the scaled, high-quality development of Guangdong's CGT industry and contributing to the innovation and upgrading of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

Guangzhou Yuexiu Health Technology Co., Ltd.

Guangzhou Yuexiu Health Technology Co., Ltd. is a newly established stateowned holding company under Yuexiu Group, founded in February 2026, marking the Group's new strategic move into the health technology and services sector. Yuexiu Group was established in Hong Kong in 1985. After 40 years of reform and development, the Group has formed a "4+X" modern industrial system, with core industries including finance, real estate, transportation infrastructure, and food, alongside traditional industries such as papermaking and strategically emerging industries that may be entered in the future. It is a "Double Hundred Enterprise" under the State Council's stateowned enterprise reform program. In 2025, the Group's consolidated assets reached 1,059.6 billion yuan, achieving operating revenue of 127.7 billion yuan (up 1% yearonyear) and total profit of 6.5 billion yuan (up 30% yearonyear). The Group ranked 209th among China's Top 500 Enterprises in 2025 and 10th among China's Top 100 Transnational Corporations. Yuexiu Group holds six listed platforms: Yuexiu Capital, Yuexiu Property, Yuexiu Transport Infrastructure, Yuexiu Real Estate Investment Trust, Yuexiu Services, and China Yuexiu Expressway REIT.